netFormulary Leicestershire Health Community NHS
Medicines Formulary  
 Formulary Chapter 2: Cardiovascular system - Full Chapter
02.02.01  Expand sub section  Thiazides and related diuretics
 note  See section 2.2
  • The action of indapamide is progressive and the reduction in blood pressure may continue and not reach a maximum until several months after the start of therapy.
  • Indapamide is claimed to lower blood pressure with less metabolic disturbance than other diuretics particularly less aggravation of diabetes mellitus.
  • Metolazone and loop diuretics appear to have a synergistic effect when combined. Profound diuresis can occur so monitor patient carefully. Use intermittently based on achievement of a target weight. Reduce dose or stop treatment until target weight exceeded again.
  • Indapamide 2.5mg
    View adult BNF View SPC online  Track Changes
    First Choice
    If a diuretic is to be initiated or changed. Existing patients should remain on bendroflumethiazide.
    NB Indapamide MR is not recommended as limited evidence of additional benefits and higher cost.

    View adult BNF View SPC online  Track Changes
    Restricted Drug Restricted
    Amber Simple
    Oedema resistant to large doses of loop diuretics alone.
    This product has been discontinued by the manufacturers but imported sources are now available. Local specialist opinion is to use bendroflumethiazide as an alternative in line with the recommendations of the British Society for Heart Failure. 
    Link  British Society for Heart Failure statement: Metolazone withdrawal
     Non Formulary Items
    Indapamide SR  (Natrilix-SR)

    View adult BNF View SPC online Track Changes
    Non Formulary
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Track Changes
    Display tracking information
    click to search
    Link to adult BNF
    click to search
    Link to children's BNF
    click to search
    Link to SPCs
    Scottish Medicines Consortium
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHS England

    Traffic Light Status Information

    Status Description


    Drugs not recommended for use in the Leicestershire Health Community because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety. All new drugs will be black until they have been through the appropriate approval process - then they will appear as a specific entry   


    Drugs which should be prescribed only by hospital specialists (clinical review by specialist as appropriate and annually as a minimum).  

    Amber SCA

    Drugs which would initially be prescribed by a hospital specialist and then by a GP where full agreement to share the care of each specific patient has been reached under a LMSG Shared Care Agreement (SCA). Specific patient monitoring or intervention required.   

    Amber Simple

    Drugs suitable to be initiated and prescribed in primary care only after specialist assessment and recommendation. A shared care agreement is not required.  

    Green Conditional

    Drugs for which GPs are able to take full responsibility for prescribing and monitoring subject to specified conditions e.g. prescribing in line with agreed LMSG guidance or able to demonstrate suitable competence see comments under individual entries.   


    Drugs for which GPs would normally take full responsibility for prescribing and monitoring. Drugs included in this list have been specifically considered by LMSG.